The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in Perimenopause

Sponsor

University of Johannesburg (Other)

Overall Status

Completed

CT.gov ID

NCT02419209

Collaborator

(none)

Enrollment

Location

Arm

Duration (Months)

1.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Low sexual desire, or decreased libido, is one of the most prevalent sexual complaints in females. Menopause is defined as the physiologic cessation of menses brought on by a decrease in ovarian function and is established once menses have been absent for at least twelve months. Perimenopause refers to the period shortly before as well as the twelve months after the last menstrual period. The duration of perimenopause varies greatly and signs and symptoms usually begin appearing during a woman's forties. A longitudinal study conducted in Seattle showed that women experienced a significant reduction in sexual desire during the late perimenopausal and early postmenopausal stages, with the biggest decline in sexual desire occurring from three years prior to two years after the final menstrual period. Despite being a prevalent female complaint, currently no standard treatment for low sexual desire exists. Homeopathy may offer a safe and effective solution for this common problem, however limited research has been conducted to date.

The aim of this study is to explore the effect of individualised homeopathic treatment on low sexual desire in perimenopausal females using detailed case studies, the desire and arousal subscales of the Female Sexual Function Index (FSFI) as well as Item 13 of the Female Sexual Distress Scale - Revised (FSDS-R).

Condition or Disease	Intervention/Treatment	Phase
Hypoactive Sexual Desire Disorder	Other: Sucrose pillules medicated with the Individualised Homeopathic Remedy	Phase 2

Detailed Description

This study is an embedded mixed method case study design and will take place at the University of Johannesburg Homeopathic Health Centre, Doornfontein Campus, over a period of twelve weeks. These twelve weeks will consist of four consultations per participant at four week intervals. Ten female participants aged 40-60 years who meet the inclusion criteria will be recruited by means of advertisements placed at the University of Johannesburg Doornfontein Campus as well as at pharmacies and health shops in the Gauteng area (with relevant permission given).

Once the volunteers agree to participate in the study, they will be requested to sign a Participant Information and Consent Form at the start of the initial consultation. Participants will also be requested to complete a screening questionnaire in order to determine whether they meet the inclusion and exclusion criteria. A complete case history will be taken for each participant who fits the inclusion criteria, using a detailed homeopathic case-taking form; vital signs will be checked and any necessary physical examinations will be performed. Participants will also complete the relevant Female Sexual Function Index (FSFI) subscales and Item 13 of the Female Sexual Distress Scale- Revised (FSDS-R).

The appropriate individualised homeopathic remedy for each participant will be selected using Mercurius Repertorisation Software Complete Repertory 2014 and the appropriate homeopathic Materia Medicas, under supervision of the attending clinician. At the follow-up consultations the case will be re-taken and the homeopathic medicine will either be repeated or changed based on the response of the participant to the medication previously administered following the principles of homeopathic prescribing. A relevant physical exam will be conducted, and participants will complete the relevant subscales of the FSFI and item 13 of the FSDS-R at each of the four consultations.

All data will be collected by the researcher during the course of the study. Qualitative data obtained from detailed case-takings will be used to write descriptive case studies. The FSFI subscales and FSDS-R Item 13 will be used to assess changes in desire and arousal across time and will be represented graphically. Due to the small sample size and qualitative nature of the cases no statistical analysis will be completed.

The outcome of this study may possibly indicate the effectiveness of individualised homeopathic treatment in low sexual desire associated with perimenopause. This study may provide the groundwork for future research on the effect of homeopathy on low sexual desire in females.

Study Design

Study Type:

Interventional

Actual Enrollment :

10 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in Perimenopause

Study Start Date :

Jan 1, 2015

Actual Primary Completion Date :

Oct 1, 2015

Actual Study Completion Date :

Oct 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Individualised Homeopathic Remedy A single individualised homeopathic remedy will be administered to each participant in the form of medicated sucrose pillules. The potency, dosage and frequency of administration will be individualised for each participant in accordance with the laws that govern homeopathic prescribing.	Other: Sucrose pillules medicated with the Individualised Homeopathic Remedy Sucrose pillules medicated with the Individualised Homeopathic Remedy and potency as selected by the researcher in accordance with the laws that govern individualised homeopathic prescribing.

Arm

Intervention/Treatment

Experimental: Individualised Homeopathic Remedy

A single individualised homeopathic remedy will be administered to each participant in the form of medicated sucrose pillules. The potency, dosage and frequency of administration will be individualised for each participant in accordance with the laws that govern homeopathic prescribing.

Other: Sucrose pillules medicated with the Individualised Homeopathic Remedy

Sucrose pillules medicated with the Individualised Homeopathic Remedy and potency as selected by the researcher in accordance with the laws that govern individualised homeopathic prescribing.

Outcome Measures

Primary Outcome Measures

Female Sexual Function Index [Every fourth week for twelve weeks.]
The Female Sexual Function Index (FSFI) covers six domains of female sexual function namely: desire, subjective arousal, lubrication, orgasm, satisfaction and pain. The study has shown a high test-retest reliability and a high degree of internal consistency for each of the six domains.

Secondary Outcome Measures

The Female Sexual Distress Scale (FSDS-R) [Every fourth week for twelve weeks.]
The FSDS-R can be used to identify distress related to sexual function, as well as to support a potential diagnosis of sexual dysfunction. It has demonstrated the discriminant validity and test-retest reliability of both the FSDS-R and FSDS-R Item 13 alone in women suffering from Hypoactive Sexual Desire Disorder. Item 13 of the scale specifically pertains to low sexual desire and has been demonstrated to have good content validity, thereby making it sufficient as a stand-alone measure for low sexual desire.
Individual participant case histories [Every fourth week for twelve weeks]
Individual case histories of each participant will be recorded during each consultation, by means of the researcher's case notes, in order to collect qualitative data.

Eligibility Criteria

Criteria

Ages Eligible for Study:

40 Years to 60 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Females aged 40-60 years who are perimenopausal (up to one year after final menses)
Low sexual desire present for the last 3 months
At least 2 of the additional common signs and symptoms of perimenopause present for the last 3 months such as menorrhagia, irregular menses, amenorrhoea, hot flushes, night sweats, heart palpitations, insomnia, fatigue, mood swings, irritability, anxiety, memory and/or concentration loss, headaches, joint pain and vaginal dryness
History of normal libido, with onset of low sexual desire coinciding with or appearing after the onset of other symptoms of perimenopause.

Exclusion Criteria:

Cessation of menses for more than 1 year (postmenopause)
Total hysterectomy
Early menopause (before age 40)
Pelvic or abdominal surgery in the preceding 6 months
Pregnant or lactating women or childbirth in the preceding 12 months
Gynaecological disorders such as endometriosis, uterine fibroids, dyspareunia or vaginismus
Chronic diseases that affect sexual desire
Chronic medication that can affect sexual desire such as: Hormone Replacement Therapy, oral contraceptives, anti-depressants, benzodiazepines, beta-blockers, opioids, carbamazepine or antihistamines.